GlassScriptPhysician profile
Tracie Price
NPI 1295064798
$49,296.86
in general payments reported to CMS, 2019-2025
64 companies · $3,792 in 2025
The $3,792 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27K · 2022: $11K · 2023: $3,373 · 2024: $4,126 · 2025: $3,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $54.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,226.26 |
| Education | $54.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28,687.91 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,987.89 | 2022 | |
| Ucb, INC. | $2,035.64 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Mdd US Operations, LLC | $957.03 | 2021-2025 | Gocovri, Apokyn, Apokyn |
| Novartis Pharmaceuticals Corporation | $952.78 | 2021-2025 | |
| Allergan, INC. | $838.33 | 2021 | |
| Neurelis, INC. | $802.55 | 2021-2025 | Valtoco |
| Lundbeck LLC | $760.56 | 2021-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $703.93 | 2021-2025 | Ultomiris, Soliris |
| Biogen, INC. | $678.44 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Avanir Pharmaceuticals, INC. | $523.64 | 2021-2022 | |
| Lilly USA, LLC | $516.09 | 2021-2025 | Kisunla, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $469.69 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $392.40 | 2021-2025 | |
| Tg Therapeutics, INC. | $363.60 | 2023-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $362.77 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $329.77 | 2021 | |
| Jazz Pharmaceuticals INC. | $313.54 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $309.21 | 2021-2023 | Ponvory |
| Argenx US, INC. | $291.29 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $282.68 | 2021-2025 | Nuplazid |
| Amgen INC. | $275.29 | 2021-2025 | Aimovig, Uplizna, Repatha |
| Harmony Biosciences LLC | $265.46 | 2022-2024 | Wakix |
| Neurocrine Biosciences, INC. | $249.35 | 2021-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $248.54 | 2021-2025 | |
| Genentech USA, INC. | $248.10 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Sk Life Science, INC. | $244.02 | 2021-2025 | |
| Kyowa Kirin, INC. | $200.92 | 2021-2024 | Nourianz |
| Scilex Pharmaceuticals INC. | $182.63 | 2023-2025 | Ztlido |
| Csl Behring | $182.39 | 2021-2025 | Hizentra |
| Grifols USA, LLC | $181.63 | 2021-2025 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $179.29 | 2023-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $177.31 | 2021-2025 | Xeomin, Inbrija |
| Catalyst Pharmaceuticals, INC. | $170.71 | 2021-2025 | Fycompa |
| Abbott Laboratories | $156.18 | 2021-2025 | Infinity |
| Ipsen Biopharmaceuticals, INC | $155.00 | 2021-2025 | Dysport |
| Amneal Pharmaceuticals LLC | $149.12 | 2021-2025 | Rytary, Crexont |
| Medtronic, INC. | $148.14 | 2022-2025 | Percept PC Brainsense, Sensight |
| Corium, LLC | $136.94 | 2022-2023 | Adlarity |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Emd Serono, INC. | $105.40 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $96.89 | 2023-2024 | Aptiom |
| Mallinckrodt Hospital Products INC. | $86.82 | 2021-2024 | Acthar |
| Impel Pharmaceuticals INC. | $75.24 | 2023 | Trudhesa |
| Sunovion Pharmaceuticals INC. | $74.15 | 2021 | |
| Idorsia Pharmaceuticals US INC | $64.61 | 2023 | Quviviq |
| Tanabe Pharma America, INC. | $58.77 | 2024-2025 | Radicava |
| Astrazeneca Pharmaceuticals LP | $53.30 | 2023-2025 | Wainua |
| Celgene Corporation | $51.46 | 2021 | |
| Axsome Therapeutics, INC. | $50.18 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $49.02 | 2025 | Hyqvia |
| Amylyx Pharmaceuticals, INC. | $34.37 | 2024 | Relyvrio |
| Boston Scientific Corporation | $31.99 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $31.65 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $31.38 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.20 | 2021 | |
| Aucta Pharmaceuticals, INC. | $21.95 | 2025 | Motpoly Xr |
| Tonix Medicines, INC. | $20.25 | 2025 | Tonmya |
| Hospira, INC. | $19.88 | 2022 | |
| Acorda Therapeutics, INC | $18.72 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.18 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.82 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.74 | 2023 | Horizant |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.